🎥 2 New Shocking Studies On Myocarditis From Pfizer & Moderna Surface | France & Ontario Studies
Two new peer reviewed studies emerged over the past week showing shocking numbers of myocarditis post mRNA vaccination from Pfizer and Moderna, one study from France, and one from Ontario, Canada. I breakdown each study in this video
SUBSTACK POST FROM THIS VIDEO:
https://jamescintolo.substack.com/p/breaking-2-new-shocking-studies-on
REFERENCES:
https://pubmed.ncbi.nlm.nih.gov/7596370/
LETS CONNECT:
Wow. Thanks for bringing this to our attention and further confirming more of what awakened people suspected.
I've heard that, traditionally, myocarditis is basically a 5- to 10-year death-sentence for 50% of the people (but I should check the stats on that).
It's very rare for a young, healthy person to die of covid-19. I think I heard that it was less than 1000 (but don't quote me on that, as I have to check the stats).
Anyway, what I'd like to do is run a risk-benefit equation and see how many doses it would take to "prevent" one hospitalization or death vs. the side effects of those doses. (I know that there's a figure called Number Needed to Treat. I can use that and the data from these studies to arrive at an estimation.)
I'm sure there are others who have done this, but with the new info coming out, it seems to increasingly be the case that the cost-benefit ratio of these vaccines don't make them seem very appealing.
And on the topic of risk-benefit, around the 23rd, a study titled, "Serious Adverse Events of Special Interest Following mRNA Vaccination in Randomized Trials," was published. It said:
"Combined, the mRNA vaccines were associated with an absolute risk increase of serious adverse events of special interest of 12.5 per 10,000 (95% CI 2.1 to 22.9). The excess risk of serious adverse events of special interest surpassed the risk reduction for COVID-19 hospitalization relative to the placebo group in both Pfizer and Moderna trials (2.3 and 6.4 per 10,000 participants, respectively)."
https://papers.ssrn.com/sol3/papers.cfm?abstract_id=4125239